Thursday, 19 November 2026 X LinkedIn Bluesky RSS Send us news
LungDaily The Pulse of Respiratory Health
World COPD Day was on Wednesday 18 November · #WorldCOPDDay Our coverage →
New Paper Alert

SGLT-2 inhibitors linked to lower chronic lower respiratory disease risk in type 2 diabetes

Two target trial emulations using Shenzhen health data found SGLT-2 inhibitor users had a lower incidence of chronic lower respiratory disease than users of GLP-1 receptor agonists or DPP-4 inhibitors.

“Compared with GLP-1 RA, SGLT-2i were associated with a significantly lower risk of CLRDs, driven predominantly by bronchitis”— Yuhao Li, Yiqiao Lv, Yongqi Dai et al.

Adults with type 2 diabetes who used sodium-glucose cotransporter 2 inhibitors (SGLT-2i) had a lower incidence of chronic lower respiratory disease (CLRD) than users of two other drug classes, according to a study in Respiratory Research.

The researchers, led by Yuhao Li, Yiqiao Lv and Yongqi Dai, used the Shenzhen Public Health Data Platform. They ran two independent target trial emulations with a new-user active comparator design, comparing SGLT-2i with glucagon-like peptide-1 receptor agonists (GLP-1RA) and with dipeptidyl peptidase-4 inhibitors (DPP-4i). The primary outcome was incident CLRD. Secondary outcomes were bronchitis, bronchiectasis, asthma, chronic obstructive pulmonary disease and emphysema. Hazard ratios were estimated with overlap-weighted Cox models.

Over a median follow-up of 1.76 years, new CLRD cases occurred in 349 SGLT-2i users (7.95%) and 397 GLP-1RA users (9.04%). Against GLP-1RA, SGLT-2i use was associated with lower CLRD incidence (HR 0.87, 95% CI 0.79-0.96). The authors said this was driven mainly by bronchitis (HR 0.89, 95% CI 0.79-1.00) and asthma (HR 0.77, 95% CI 0.58-1.01). No significant associations were found for the other subtypes.

Against DPP-4i, SGLT-2i use showed a trend toward lower CLRD risk (HR 0.95, 95% CI 0.91-0.99). Reductions were reported for bronchitis (HR 0.95, 95% CI 0.91-1.00), bronchiectasis (HR 0.86, 95% CI 0.75-1.00) and asthma (HR 0.87, 95% CI 0.77-0.98).

Subgroup analyses showed a significant interaction by sex for bronchiectasis (P interaction = 0.001). Relative to DPP-4i, the association between SGLT-2i use and lower bronchiectasis risk was more pronounced in women than in men.

Original source

Association between sodium-glucose cotransporter 2 inhibitors and the risk of chronic lower respiratory disease in type 2 diabetes mellitus: findings from two target trial emulations. Respiratory research · https://pubmed.ncbi.nlm.nih.gov/43053103/

#asthma#bronchiectasis#copd#therapeutics

Related stories

More in New Paper Alert

See all

LungDaily reports on public posts, papers and news from the lung health community. This article is based on the source linked above and was produced with AI-assisted tools under our editorial standards; facts and quotes are checked against the original before publication. Featured here, or spotted an error? Request a correction or removal.